SCHEMBL4510050

SCHEMBL4510050

COc1ccc(C2(C(=O)Nc3nnc(C(=O)Nc4ccc(N5CCN(C(C)=O)CC5)cc4)o3)CCCC2)cc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DGAT1 O75907 6/20 0.67
MAPT P10636 7/20 0.52
KDM4E B2RXH2 4/20 0.52
ALDH1A1 P00352 4/20 0.52
HPGD P15428 3/20 0.50
KMT2A Q03164 3/20 0.50
CYP2C9 P11712 1/20 0.50
LMNA P02545 2/20 0.46
RAB9A P51151 2/20 0.46
NR4A1 P22736 1/20 0.46
MCL1 Q07820 1/20 0.46
CYP3A4 P08684 1/20 0.45
CYP2C19 P33261 1/20 0.45
SMN1; SMN2 Q16637 2/20 0.44
NPSR1 Q6W5P4 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
NPC1 O15118 1/20 0.44
USP2 O75604 1/20 0.44
HIF1A Q16665 1/20 0.44
GAA P10253 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4511620 0.97 DGAT1 (0.61) DGAT1MAPTKDM4EALDH1A1HPGD
SCHEMBL4512056 0.91 DGAT1 (0.68) DGAT1MAPTKDM4EALDH1A1HPGD
SCHEMBL4506673 0.91 DGAT1 (0.81) DGAT1MAPTALDH1A1HPGDKMT2A
SCHEMBL4507546 0.91 DGAT1 (0.67) DGAT1MAPTALDH1A1HPGDKMT2A
SCHEMBL4496999 0.90 DGAT1 (0.80) DGAT1MAPTHPGDKMT2ALMNA
SCHEMBL4510806 0.89 DGAT1 (0.81) DGAT1MAPTALDH1A1HPGDKMT2A
SCHEMBL4512985 0.87 DGAT1 (0.75) DGAT1MAPTALDH1A1HPGDKMT2A
SCHEMBL4517504 0.87 DGAT1 (0.64) DGAT1MAPTALDH1A1HPGDKMT2A
SCHEMBL4500971 0.85 DGAT1 (0.59) DGAT1MAPTKMT2ALMNARAB9A
SCHEMBL4517725 0.84 DGAT1 (0.62) DGAT1MAPTKDM4EALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090215779-A1 OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS ASTRAZENECA AB (SE) 2009-08-27 US claimed
EP-1893592-A1 OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS AstraZeneca AB (SE) 2008-03-05 EP claimed
WO-2006134317-A1 OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS ASTRAZENECA AB (SE) 2006-12-21 WO claimed
US-20090215779-A1 OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS ASTRAZENECA AB (SE) 2009-08-27 US disclosed
EP-1893592-A1 OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS AstraZeneca AB (SE) 2008-03-05 EP disclosed
WO-2006134317-A1 OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS ASTRAZENECA AB (SE) 2006-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090215779-A1 OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS DGAT2, GPR119, DGAT1 DGAT1 3/4885MAPT 2561/4885KDM4E 3220/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.